Showing results (61-70 of 227) with videos related to

Sort By:
Pageof 23
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 13, 2025
Remission Assessment by Circulating Tumor DNA in Large B-cell LymphomaMark Roschewski, David M Kurtz, Jason R Westin, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 8, 2017
Posterior Reversible Encephalopathy Syndrome Associated With Dose-adjusted EPOCH (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) ChemotherapyAbby E Floeter, Amila Patel, Melinda Tran, et al.
Blood Advances|January 4, 2018
Management of venous thromboembolism during thrombocytopenia after autologous hematopoietic cell transplantationAng Li, Chris Davis, Qian Wu, et al.
Blood Advances|December 15, 2022
Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomasRyan C Lynch, Christina Poh, Chaitra S Ujjani, et al.
The Lancet. Haematology|July 30, 2021
Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 studyRyan C Lynch, Ryan D Cassaday, Stephen D Smith, et al.
Plos One|September 8, 2011
Global distribution of Polaromonas phylotypes--evidence for a highly successful dispersal capacityJohn L Darcy, Ryan C Lynch, Andrew J King, et al.
Experimental Hematology|January 25, 2017
Androgen receptor expression in mantle cell lymphoma: Potential novel therapeutic implicationsElahe A Mostaghel, Paul S Martin, Stephen Mongovin, et al.
Frontiers in Microbiology|January 8, 2015
Metagenomic evidence for metabolism of trace atmospheric gases by high-elevation desert ActinobacteriaRyan C Lynch, John L Darcy, Nolan C Kane, et al.
Blood|May 22, 2012
Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphomaRobert Chen, Joycelynne M Palmer, Sandra H Thomas, et al.
Anti-Cancer Drugs|August 4, 2015
Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and IκBα kinase downregulationAndrew J Cowan, Shani L Frayo, Oliver W Press, et al.
Pageof 23